Exagen Share Price Today
(NASDAQ: XGN)

Name: Exagen Share Price Today (NASDAQ: XGN) - Exagen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Exagen share price is $3.19 & ₹277.43 as on 6 Mar 2025, 2.30 'hrs' IST

$3.19

▲

0.18

(5.98%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Exagen share price in Dollar and Rupees. Guide to invest in Exagen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Exagen, along with analyst recommendations, forecasts, and comprehensive financials.

Exagen share price movements

Today's Low: $2.82
Today's High: $3.27
$3.19
11.6%
Downside
Day's Volatility :13.76%
Upside
2.45%
52 Weeks Low: $1.30
52 Weeks High: $6.22
$3.19
59.24%
Downside
52 Weeks Volatility :79.09%
Upside
48.71%

Exagen (XGN) Returns

Period	Exagen Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-27.83%	3.7%	0.0%
6 Months	-6.73%	-2.8%	0.0%
1 Year	61.63%	2.5%	0.0%
3 Years	-57.18%	12.9%	-11.6%

Exagen (XGN) Key Statistics

in dollars & INR

Previous Close	$3.01
Open	$3.0
Today's High	$3.27
Today's Low	$2.82
Market Capitalization	$53.1M
Today's Volume	$50.8K
52 Week High	$6.22
52 Week Low	$1.3003
Revenue TTM	$55.8M
EBITDA	$-13.6M
Earnings Per Share (EPS)	$-0.92
Profit Margin	-30.36%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-83.86%

How to invest in Exagen Stock (XGN) from India?

It is very easy for Indian residents to invest directly in Exagen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Exagen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Exagen or XGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Exagen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Exagen shares which would translate to 0.273 fractional shares of Exagen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Exagen, in just a few clicks!

Returns in Exagen (XGN) for Indian investors in Rupees

The Exagen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Exagen investment value today

Current value as on today

₹1,66,878

Returns

₹66,878

(+66.88%)

Returns from Exagen Stock

₹61,929 (+61.93%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Exagen (XGN)

17%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Exagen Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Exagen

RTW INVESTMENTS, LLC
8.57%
The Toronto-Dominion Bank
5.05%
COWEN AND COMPANY, LLC
5.05%
Silvercrest Asset Management Group LLC
3.03%
Vanguard Group Inc
2.78%
Morgan Stanley - Brokerage Accounts
2.74%

Analyst Recommendation on Exagen

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Exagen(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Exagen Stock (XGN)

What analysts predicted

Upside of 119.44%

Target:

$7.00

Current:

$3.19

Insights on Exagen Stock (Ticker Symbol: XGN)

Price Movement
In the last 7 days, XGN stock has moved down by -10.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 15.06M → 12.50M (in $), with an average decrease of 17.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -2.96M → -5.02M (in $), with an average decrease of 69.5% per quarter
XGN vs TMO (3 yr)
In the last 3 years, Exagen Inc has experienced a drawdown of -56.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 52.1%

XGN Exagen Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$32.4M	↑ 21.01%
Net Income	$-8.0M	↓ 68.74%
Net Profit Margin	-24.7%	↑ 70.91%

	FY19	Y/Y Change
Revenue	$40.4M	↑ 24.5%
Net Income	$-12.0M	↑ 50.25%
Net Profit Margin	-29.81%	↓ 5.11%

	FY20	Y/Y Change
Revenue	$42.0M	↑ 3.93%
Net Income	$-16.7M	↑ 38.62%
Net Profit Margin	-39.75%	↓ 9.94%

	FY21	Y/Y Change
Revenue	$48.3M	↑ 15.07%
Net Income	$-26.9M	↑ 60.91%
Net Profit Margin	-55.59%	↓ 15.84%

	FY22	Y/Y Change
Revenue	$45.6M	↓ 5.66%
Net Income	$-47.4M	↑ 76.48%
Net Profit Margin	-104.0%	↓ 48.41%

	FY23	Y/Y Change
Revenue	$52.5M	↑ 15.33%
Net Income	$-23.7M	↓ 50.01%
Net Profit Margin	-45.08%	↑ 58.92%

	Q2 FY23	Q/Q Change
Revenue	$14.1M	↑ 25.89%
Net Income	$-5.0M	↓ 39.66%
Net Profit Margin	-35.46%	↑ 38.52%

	Q3 FY23	Q/Q Change
Revenue	$13.4M	↓ 5.1%
Net Income	$-5.4M	↑ 8.02%
Net Profit Margin	-40.36%	↓ 4.9%

	Q4 FY23	Q/Q Change
Revenue	$13.8M	↑ 2.6%
Net Income	$-5.6M	↑ 2.92%
Net Profit Margin	-40.49%	↓ 0.13%

	Q1 FY24	Q/Q Change
Revenue	$14.4M	↑ 4.72%
Net Income	$-3.4M	↓ 39.71%
Net Profit Margin	-23.31%	↑ 17.18%

	Q2 FY24	Q/Q Change
Revenue	$15.1M	↑ 4.5%
Net Income	$-3.0M	↓ 11.73%
Net Profit Margin	-19.69%	↑ 3.62%

	Q3 FY24	Q/Q Change
Revenue	$12.5M	↓ 16.97%
Net Income	$-5.0M	↑ 69.52%
Net Profit Margin	-40.2%	↓ 20.51%

	FY18	Y/Y Change
Profit	$17.1M	↑ 34.66%

	FY19	Y/Y Change
Profit	$21.6M	↑ 26.48%

	FY20	Y/Y Change
Profit	$25.4M	↑ 17.78%

	FY21	Y/Y Change
Profit	$27.7M	↑ 9.03%

	FY22	Y/Y Change
Profit	$21.3M	↓ 22.96%

	FY23	Y/Y Change
Profit	$29.5M	↑ 37.97%

	Q2 FY23	Q/Q Change
Profit	$8.3M	↑ 56.5%

	Q3 FY23	Q/Q Change
Profit	$7.7M	↓ 7.17%

	Q4 FY23	Q/Q Change
Profit	$8.1M	↑ 5.7%

	Q1 FY24	Q/Q Change
Profit	$8.6M	↑ 5.56%

	Q2 FY24	Q/Q Change
Profit	$9.1M	↑ 5.33%

	Q3 FY24	Q/Q Change
Profit	$7.0M	↓ 22.91%

	FY18	Y/Y Change
Operating Cash Flow	$-9.3M	↓ 15.2%
Investing Cash Flow	$-199.0K	↓ 60.98%
Financing Cash Flow	$11.4M	↓ 40.37%

	FY19	Y/Y Change
Operating Cash Flow	$-9.7M	↑ 4.41%
Investing Cash Flow	$-103.0K	↓ 48.24%
Financing Cash Flow	$68.7M	↑ 501.72%

	FY20	Y/Y Change
Operating Cash Flow	$-14.1M	↑ 45.03%
Investing Cash Flow	$-455.0K	↑ 341.75%
Financing Cash Flow	$-97.0K	↓ 100.14%

	FY21	Y/Y Change
Operating Cash Flow	$-20.3M	↑ 43.92%
Investing Cash Flow	$-2.4M	↑ 431.87%
Financing Cash Flow	$64.7M	↓ 66783.51%

	FY22	Y/Y Change
Operating Cash Flow	$-32.1M	↑ 58.59%
Investing Cash Flow	$-4.3M	↑ 78.43%
Financing Cash Flow	$-489.0K	↓ 100.76%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-10.2M	↑ 4.15%
Investing Cash Flow	$-322.0K	↓ 18.69%
Financing Cash Flow	$-10.2M	↑ 16419.35%

Exagen Technicals Summary

Sell

Neutral

Buy

Exagen is currently in a neutral trading position according to technical analysis indicators.

Exagen (XGN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Exagen Inc	-36.45%	-6.73%	61.63%	-57.18%	-84.42%
Agilent Technologies Inc.	-13.96%	-8.56%	-13.48%	-2.94%	78.81%
Idexx Laboratories, Inc.	-5.98%	-6.81%	-21.57%	-15.48%	80.06%
Thermo Fisher Scientific, Inc.	-9.71%	-13.63%	-11.38%	-1.97%	77.48%
Danaher Corp.	-2.07%	-20.46%	-16.74%	-19.95%	48.71%
Iqvia Holdings Inc.	-7.09%	-25.1%	-26.53%	-14.22%	49.88%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Exagen Inc	NA	NA	NA	-0.87	-0.84	-0.18	NA	0.73
Agilent Technologies Inc.	29.02	29.02	2.0	5.57	0.21	0.08	0.01	21.13
Idexx Laboratories, Inc.	41.39	41.39	4.36	11.97	0.58	0.23	NA	19.55
Thermo Fisher Scientific, Inc.	31.65	31.65	2.02	23.33	0.13	0.05	0.0	130.22
Danaher Corp.	38.92	38.92	2.05	7.65	0.08	0.04	0.01	68.9
Iqvia Holdings Inc.	24.81	24.81	0.98	11.89	0.23	0.05	NA	34.45

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Exagen Inc	Buy	$53.1M	-84.42%	NA	-30.36%
Agilent Technologies Inc.	Buy	$36.1B	78.81%	29.02	19.27%
Idexx Laboratories, Inc.	Buy	$35.9B	80.06%	41.39	22.78%
Thermo Fisher Scientific, Inc.	Buy	$194.9B	77.48%	31.65	14.77%
Danaher Corp.	Buy	$147.2B	48.71%	38.92	16.33%
Iqvia Holdings Inc.	Buy	$32.8B	49.88%	24.81	8.91%

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Organization	Exagen
Employees	174
CEO	Mr. John Aballi
Industry	Health Services

Management People of Exagen

Name	Title
Dr. Tina S. Nova Ph.D.	Executive Chairman of the Board of Directors
Mr. John Aballi	CEO, President & Director
Mr. Kamal Adawi M.S., MBA	Corporate Secretary
Mr. Jeffrey G. Black	Chief Financial Officer
Mr. Ryan Douglas	Investors Relations Officer
Dr. Michael I. Nerenberg M.D.	Chief Medical Officer

Important FAQs about investing in XGN Stock from India :

What is Exagen share price today?

Exagen share price today stands at $3.19, Open: $3.00 ; Previous Close: $3.01 ; High: $3.27 ; Low: $2.82 ; 52 Week High: $6.22 ; 52 Week Low: $1.30.

The stock opens at $3.00, after a previous close of $3.01. The stock reached a daily high of $3.27 and a low of $2.82, with a 52-week high of $6.22 and a 52-week low of $1.30.

Can Indians buy Exagen shares?

Yes, Indians can invest in the Exagen (XGN) from India.

With INDmoney, you can buy Exagen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Exagen at zero transaction cost.

How can I buy Exagen shares from India?

It is very easy to buy Exagen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Exagen (XGN) be purchased?

Yes, you can buy fractional shares of Exagen with INDmoney app.

What are the documents required to start investing in Exagen stocks?

To start investing in Exagen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.